Insider Transactions in Q2 2021 at Lyell Immunopharma, Inc. (LYEL)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2021
|
Cathy Friedman |
BUY
Open market or private purchase
|
Indirect |
17,648
+50.0%
|
$300,016
$17.0 P/Share
|
|
Jun 21
2021
|
Cathy Friedman |
BUY
Conversion of derivative security
|
Indirect |
3,765,842
+50.0%
|
-
|
|
Jun 21
2021
|
Hans Edgar Bishop |
BUY
Conversion of derivative security
|
Direct |
546,806
+13.36%
|
-
|
|
Jun 21
2021
|
Richard Klausner |
BUY
Conversion of derivative security
|
Indirect |
3,765,842
+50.0%
|
-
|
|
Jun 21
2021
|
Robert Nelsen |
BUY
Conversion of derivative security
|
Indirect |
36,412,716
+50.0%
|
-
|
|
Jun 21
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
36,412,716
+50.0%
|
-
|
|
Jun 21
2021
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
30,253,189
+50.0%
|
-
|